Drug Profile
VXA BYW 10
Alternative Names: Influenza B Oral Vaccine - Vaxart; VXA-BYW-10Latest Information Update: 01 Nov 2023
Price :
$50
*
At a glance
- Originator Vaxart
- Class Antivirals; Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza B virus infections
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for phase-I development in Influenza-B-virus-infections(Prevention) in New Zealand (PO, Tablet)
- 01 Nov 2015 Phase-I clinical trials in Influenza-B virus infections (Prevention) in New Zealand (PO) (NCT02547792)